新闻动态

文章发表

科学探索 着力创新

/
文章发表
T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity
T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity
Phase I Study of BI 853520【IN10018】, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
Phase I Study of BI 853520【IN10018】, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
Abstract LB-021: Focal adhesive kinase inhibitor IN10018 sensitizes KRAS mutant cancer and overcomes drug resistance of KRAS G12C inhibition
Abstract LB-021: Focal adhesive kinase inhibitor IN10018 sensitizes KRAS mutant cancer and overcomes drug resistance of KRAS G12C inhibition
The FAK inhibitor BI 853520 【IN10018】exerts anti-tumor effects in breast cancer
The FAK inhibitor BI 853520 【IN10018】exerts anti-tumor effects in breast cancer
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype
The FAK inhibitor BI 853520 【IN10018】 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
The FAK inhibitor BI 853520 【IN10018】 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
上一页
1
应世

版权所有 © 2019  应世汇康(北京)生物科技有限公司  京ICP备19001572号-1  网站建设:中企动力  北京